Antimicrobial-treated medical face mask launched

Nov. 24, 2009
Mask has shown to be effective against H1N1 and other influenza A viruses.

HAUPPAUGE, New York--Crosstex, a division of Cantel Medical Corp., has announced the launch of the Crosstex Ultra Sensitive Medical Face Mask that is treated with BIOSAFE antimicrobial in specific markets outside the United States.

The new antimicrobial-treated medical mask has been proven effective against H1N1 and other Influenza A strains, as well as microorganisms including MRSA, Staphylococcus aureus, VRE, Enterococcus faecalis, Pseudomonas aeruginosa, and Salmonella enterica.

"BIOSAFE antimicrobial treatment enhances the superior functional capabilities of the Crosstex Ultra Sensitive Medical Face Mask, providing an unprecedented level of protection," Gary Steinberg, CEO of Crosstex, said.

"BIOSAFE antimicrobial chemically binds to the outer mask surface and begins killing the harmful microorganisms upon contact. In fact, testing confirmed that our new medical mask killed between 98.5% and 99.999% of the trapped viruses and bacteria within five minutes of contact with the mask, generating a long-lasting shield that greatly reduces the cross-contamination risk from touching the mask itself. When finished with the mask, the unique water-based antimicrobial composition of BIOSAFE furthermore allows for environmentally safer disposal than with traditional masks and those with other coating agents. The BIOSAFE antimicrobial treated medical mask, like all of our Crosstex Ultra
Sensitive Face Masks, is made in the U.S.A. and is latex-free," added Steinberg.

"We developed Ultra Sensitive Medical Face Masks treated with BIOSAFE antimicrobial to address the health-care industry's greatest infection control challenges--the current H1N1 pandemic and the growing prevalence of other harmful microorganisms," said Andrew Whitehead, vice president of sales and
marketing at Crosstex.

"As one of the largest U.S. manufacturers of face masks, we are proud to take a leading role in adapting advanced infection control technologies to meet the changing needs of today's health care professionals and their patients."

The new medical mask is being launched in specific markets outside of the United States. Within the United States, the sale of face masks treated with BIOSAFE antimicrobial for medical applications is subject to a 510(k) clearance by the U.S. Food and Drug Administration.

At this time Crosstex is awaiting publication of the latest revision of the FDA Guidance Document pertaining to antimicrobial treatments of medical devices prior to filing its application. BIOSAFE antimicrobial has passed all U.S. Environmental Protection Agency-required toxicity tests and has an approved EPA label. EPA approval covering the sale of the treated mask in the U.S. for nonmedical applications is pending.

The Ultra Sensitive Medical Face Mask treated with BIOSAFE antimicrobial is the most recent innovation in a line of infection control and preventative products from Crosstex.

For more information on the Ultra Sensitive Medical Face Mask treated with BIOSAFE antimicrobial, call Crosstex at (888) 276-7783 (toll free), (631) 582-6777or visit Crosstex.

To read more about Crosstex, go to Crosstex.

To comment on this product, go to PennWell Dental Community site.

References available upon request from company.